A recent analysis of data from a major clinical trial has shed new light on the cardiovascular benefits of semaglutide, a medication used for weight loss. The study, published in the European Heart Journal, found that semaglutide's benefits for the heart cannot be fully explained by weight loss and other traditional risk factors for cardiovascular disease. The trial, known as SELECT, involved over 17,600 adults with a history of cardiovascular disease and a body mass index of 27 or higher.
The SELECT trial found that semaglutide, administered via weekly injections of 2.4 milligrams, reduced the risk of major cardiovascular events by 20% compared to a placebo. The study's lead author, Dr. Helen M. Colhoun, noted that the analysis aimed to determine whether changes in body weight, waist circumference, blood sugar levels, and inflammation could explain the cardiovascular benefits of semaglutide. The researchers used statistical models to analyze the relationships between these factors and cardiovascular events.
The analysis revealed that changes in body weight, waist circumference, hemoglobin A1c, and high-sensitivity C-reactive protein (hsCRP) were associated with cardiovascular benefits. However, when these factors were combined in a single analysis, they only explained about 31% of the reduction in cardiovascular events. When weight loss and waist circumference were excluded from the analysis, the estimated proportion of cardiovascular benefits increased to around 46%.
Despite these findings, the researchers noted that the results were subject to significant uncertainty, and the relationships between weight loss, waist circumference, and cardiovascular events varied between the semaglutide and placebo groups. The study's authors concluded that the mechanisms underlying semaglutide's cardiovascular benefits are complex and multifaceted, and cannot be fully explained by traditional risk factors.
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, works by mimicking a hormone that regulates appetite, insulin, and glucagon. Researchers have long suspected that the medication has additional effects on the cardiovascular system, including anti-inflammatory properties and effects on blood vessels. However, the exact mechanisms underlying its cardiovascular benefits remain unclear.
The study's findings have implications for the use of semaglutide and other GLP-1 receptor agonists in clinical practice. While weight loss remains an important aspect of cardiovascular health, the results suggest that semaglutide's benefits extend beyond weight loss alone. The medication may be useful for patients with cardiovascular disease who are overweight or obese, regardless of their level of weight loss.
The study was funded by Novo Nordisk, the manufacturer of semaglutide, and some researchers disclosed relationships with the company. However, the study's findings are consistent with previous research and provide new insights into the complex relationships between semaglutide, weight loss, and cardiovascular health. Further research is needed to fully understand the mechanisms underlying semaglutide's cardiovascular benefits and to determine its potential applications in clinical practice.
Key points
- Semaglutide's cardiovascular benefits cannot be fully explained by weight loss alone.
- The medication's effects on inflammation, waist circumference, and blood sugar levels may contribute to its cardiovascular benefits.
- Further research is needed to fully understand the mechanisms underlying semaglutide's cardiovascular benefits.
